Cipla acquires InvaGen, Exelan

MUMBAI, India — Cipla announced recently that its UK arm had closed the acquisitions of two U.S.-based company. Cipla will own both InvaGen Pharmaceuticals and Exelan Pharmaceuticals, which had combined revenue in 2015 of $230 million. 

 

The acquisition of InvaGen will bring to Cipla 40 approved generic drugs and 32 marketed products, with another 30 in the pipeline. InvaGen is based in Long Island, N.Y. The Delaware-based Exelan focuses on generics for the government and institutional market and currently sells InvaGen generics to government buyers. 

 

“The acquisition will further strengthen Cipla’s presence in the US pharmaceutical market,” Cipla’s global chief operating officer Umang Vohra said. “InvaGen’s balanced portfolio, robust manufacturing base and strong R&D capabilities will act as lever to expand Cipla’s reach in the US market.”